Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Phase 2
1,200
about 1.5 years
18+
34 sites in AL, CA, FL +11
What this study is about
This trial is testing the safety of REGN7508 and REGN9933, two experimental drugs, in adults with atrial fibrillation. It compares these new drugs to apixaban, a medication already used to prevent blood clots, to see how well they work and what side effects might occur.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Apixaban
- 2.Take REGN7508
- 3.Take REGN9933
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
apixaban (Factor Xa inhibitor; prevents clot formation)
oral
Secondary: Change from baseline in Prothrombin Time (PT), Change from baseline in activated Partial Thromboplastin Time (aPTT), Incidence of Treatment-Emergent Adverse Events (TEAEs), Severity of TEAEs
Cardiology / Heart